Request Demo
Last update 08 May 2025
CLDN6 RNA-LPX
Last update 08 May 2025
Overview
Basic Info
Drug Type Therapeutic vaccine, mRNA vaccine |
Synonyms- |
Target |
Action modulators, stimulants |
Mechanism CLDN6 modulators(Claudin 6 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with CLDN6 RNA-LPXNCT06940804
Open-label Phase II Trial to Evaluate Anti-tumor Activity and Safety of CLDN6 CAR-T ± CLDN6 RNA-LPX in Male Participants With Relapsed or Refractory Claudin 6-positive Testicular or Extragonadal Germ Cell Tumors
NCT04503278
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors
100 Clinical Results associated with CLDN6 RNA-LPX
Login to view more data
100 Translational Medicine associated with CLDN6 RNA-LPX
Login to view more data
100 Patents (Medical) associated with CLDN6 RNA-LPX
Login to view more data
100 Deals associated with CLDN6 RNA-LPX
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Testicular Germ Cell Tumor | Phase 2 | - | 01 Jul 2025 | |
| CLDN6-positive Solid Tumors | Phase 1 | Australia | 16 Sep 2020 | |
| Germ Cell and Embryonal Neoplasms | Phase 1 | Australia | 16 Sep 2020 | |
| Germ Cell and Embryonal Neoplasms | Phase 1 | Netherlands | 16 Sep 2020 | |
| Germ Cell and Embryonal Neoplasms | Phase 1 | Germany | 16 Sep 2020 | |
| Germ Cell and Embryonal Neoplasms | Phase 1 | Sweden | 16 Sep 2020 | |
| Ovarian Cancer | Phase 1 | Germany | 16 Sep 2020 | |
| Ovarian Cancer | Phase 1 | Australia | 16 Sep 2020 | |
| Ovarian Cancer | Phase 1 | Sweden | 16 Sep 2020 | |
| Ovarian Cancer | Phase 1 | Netherlands | 16 Sep 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 59 | (guqffobhem) = including related to LD, occurred in 52 pts (88%). eamigjoudd (dtrpjgosng ) View more | Positive | 15 Sep 2024 | |||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free